Progestins and endometrial cancer

REFERENCES

• American Cancer Society. Cancer statistic 2000. Cancer 2000;50:12
   Google Scholar
• König M, Fersis N, Franz H, et al. Endoskopisches Sentinel-Node (ESN)-Verfahren zum laparos-kopisch assistierten Staging des Endometrium-karzinoms. Geburtsh Frauenheilk 2000;4:187–90
   Google Scholar
• Randall T, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434–40
   PubMed Web of Science ®Google Scholar
• Saeguse M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Am Cancer Soc 1998; 83:11–121
   Google Scholar
• Martin-Hirsch PL, Lilford RJ, Jarvis GJ. Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomized controlled trials. Eurj Obstet Gynecol Reprod Biol 1996;65:201–7
   Google Scholar
• Sulak PJ. Endometrial cancer and hormone replacement therapy. Endocrinol Metab Clin North Am. 1997;26: 399–412
   PubMed Web of Science ®Google Scholar
• Parazzini F, La Vecchia C, Bocciolone L, et al. The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1–16
   PubMed Web of Science ®Google Scholar
• Niwa K, Morishita S, Murase T, et al. Inhibitory effects of medroxyprogesterone acetate on mouse endometrial carcinogenesis. Jpn J Cancer Res 1995; 86:724–9
   PubMedGoogle Scholar
• WHO Collaborative Study of Neoplasia and Ste-roid Contraceptives. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 1991;49:186–90
   PubMedGoogle Scholar
• Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640–9
   PubMed Web of Science ®Google Scholar
• Leo L, Arduino S, Febo G, et al. Endometrial carcinoma in women 45 years of age or younger. Eur J Gynaecol Oncol 1996;XVII:403–5
   Google Scholar
• Bokhman JV, Chepick OF, Volkova AT, et al. Adjuvant hormone therapy ofprimary endometrial carcinoma with oxyprogesterone caproate. Gynecol Oncol 1981;11:371–8
   PubMed Web of Science ®Google Scholar
• Haylock BJ, Murrell DS, Boune H, et al. Stage I endometrial carcinoma: the role of neoadjuvant progesterone therapy. Clin Oncol 1993;5:102–6
   Google Scholar
• Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417–20
   PubMed Web of Science ®Google Scholar
• Kempson RL, Pokorny GE. Adeno carcinoma of the endometrium in women aged forty and younger. Cancer 1968;21:650–62
   PubMedGoogle Scholar
• Yamazawa K, Seki K, Matsui H, et al. Prognostic factors in young women with endometrial carcinoma: a report of 20 cases and review of literature. Int J Gynecol Cancer 2000;10:212–22
   PubMed Web of Science ®Google Scholar
• Bokhman JV, Chepick OF, Volkova ATZ, et al. Gynecol Oncol 1985;20:139–55
   PubMed Web of Science ®Google Scholar
• Farhi DC, Nosanchuk J, Silverberg SG. Endo-metrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 1986;68: 741–5
   Google Scholar
• Kim YB, Holschneider CH, Ghosh K, et al. Pro-gestin alone as primary treatment of endometrial carcinoma in premenopausal women. Cancer 1997; 79:320–7
   PubMed Web of Science ®Google Scholar
• Lee KR, Scully RE. Complex endometrial hyper-plasia and carcinoma in adolescents and young women 15 to 20 years of age. Int J Gynecol Pathol 1989;8:201–13
   PubMed Web of Science ®Google Scholar
• Sardi J, Anche zar Henry JP, Paniceres G, et al. Primary hormonal treatment for early endometrial carcinoma. Eur J Gynaecol Onco11998;XIX:565–8
   Google Scholar
• Schammel DP, Mittal KR, Kaplan K, et al. Endometrial adenocarcinoma associated with intrauterine pregnancy. Int J Gynecol Pathol 1998;17:327–35
   PubMed Web of Science ®Google Scholar
• Eddy WA. Endometrial carcinoma in Stein-Leventhal syndrome treated with hydroxypro-gesterone caproate. Am J Obstet Gynecol 1978; 131:581–5
   PubMed Web of Science ®Google Scholar
• Thornton JG, Brown LA, Wells M, et al. Primary treatment of endometrial cancer with progestagen alone. Lancet 1985;2:207–8
   PubMed Web of Science ®Google Scholar
• Zuckermann B, Lavie O, Neuman M, et al. Endo-metrial carcinoma stage I - grade II. Conservative treatment followed by a healthy twin pregnancy. Int J Gynecol Cancer 1998;8:172–4
   Web of Science ®Google Scholar
• Kimmig R, Strowitzki T, Miiller-Höcker J, et al. Conservative treatment of endometrial cancer permitting subsequent triplet pregnancy. Gynecol Oncol 1995;58:255–7
   Google Scholar
• Niwa K, Yokoyama Y, Tanaka T, et al. Successful pregnancy in a patient with endometrial carcinoma treated with medroxyprogesterone acetate. Arch Gynecol Obstet 1994;255:91–4
   PubMed Web of Science ®Google Scholar
• Zanetta G, Gabriele A, Losa G, et al. Conservative management of endometrial carcinoma with pro-longed preservation of the uterus in a young patient. Int J Gynecol Cancer 1997;7:332–4
   Web of Science ®Google Scholar
• Paulson RJ, Sauer MV, Lobo RA. Pregnancy after in vitro fertilization in a patient with stage I endo-metrial carcinoma treated with progestins. Fertil Steril 1990;54:735–6
   Google Scholar
• Mitsushita J, Told T, Kato K, et al. Endometrial carcinoma remaining after term pregnancy follow-ing conservative treatment with medroxypro-gesterone acetate. Gynecol Oncol 2000;79:129–32
   PubMed Web of Science ®Google Scholar
• O'Neill RT. Pregnancy following hormonal therapy for adenocarcinoma of the endometrium. Am J Obstet 1970;108:318–21
   PubMed Web of Science ®Google Scholar
• Vinker S, Shani A, Open M, et al. Conservative treatment of adenocarcinoma of the endometrium in young patients. Is it appropriate? Eur J Obstet Gynecol Reprod Biol 1999;83:63–5
   PubMed Web of Science ®Google Scholar
• Lai C-H, Hsueh S, Chao A-S, et al. Successful pregnancy after tamoxifen and megestrol acetate therapy for endometrial carcinoma. Br J Obstet Gynaecol 1994;101:547–9
   Google Scholar
• von Fournier D, Kubli F, Bauer M, et al. Hochdosierte Gestagen-Langzeittherapie beim Korpuskarzinom, EinfluB auf Überlebenszeit. Geburtsh Frauenheilk 1981;41:266
   PubMed Web of Science ®Google Scholar
• Lahousen M, Pickel H. Adjuvant gestagen therapy in stage I endometrial cancer. Zbl Gynecol 1988; 110:1013–17
   Google Scholar
• Urbanski K, Karolevski K, Kojs Z, et al. Adjuvant progestagen therapy in survival patients with endometrial cancer after hysterectomy. Results of one institution in a prospective clinical trial. Eur J Gynecol Oncol 1993;14(Suppl):98–104
   Google Scholar
• Quinn MA. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. Int J Gynecol Cancer 1998;8:387–891
   Web of Science ®Google Scholar
• Vergote I, Kjorstad K, Abeler V, et al. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64:1011–16
   PubMed Web of Science ®Google Scholar
• Martin-Hirsch PL, Jarvis G, Kitchener H, et al. Progestagens for endometrial cancer. In The Cochrane Library, Issue 3. Oxford Update Software: 2000
   Google Scholar
• Schmidt-Matthiesen H, Wellers H. Zur Gesta-gentherapie fortgeschrittener Korpuskarzinome. Geburtsh Frauenheilk 1968;23:520–31
   Google Scholar
• Egeler V. Gestagenbehandlung bei metastasie-rednden Korpuskarzinom. Schweiz Med Wschr 1971;101:1906–9
   PubMedGoogle Scholar
• Vavra N, Salzer H, Sevelda P, et al. Adjuvante Hormontherapie beim Mammakarzinom: Medroxyprogesteronazetat - versus Tamoxifen-Medroxyprogesteronazetat-Sequenztherapie. Gynakol Rundsch 1990;30:133–43
   PubMedGoogle Scholar
• Reifenstein EC. Hydroxyprogesterone caproate therapy in advanced endometrial cancer. Cancer 1971;27:485–502
   PubMed Web of Science ®Google Scholar
• Po dratz KC, O'Brien PC, Malkasian GD, et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985;66: 106–10
   Google Scholar
• Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a gynaecologic oncology group study. J Clin Oncol 1996;14:357–61
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose—response study by the Gynaecologic Oncology Group. J Clin Oncol 1999;17:1736–44
   PubMed Web of Science ®Google Scholar
• Crespo C, Gonzilez-Matin A, Lastra E, et al. Meta-static endometrial cancer in lung and liver: com-plete and prolonged response to hormonal therapy with progestins. Gynecol Oncol 1999;72:250–5
   PubMed Web of Science ®Google Scholar
• Cornelison TL, Baker TR, Piver MS, et al. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxypro-gesterone acetate in the treatment of endometrial carcinoma. Gynecol Oncol 1995:59:243–8
   PubMed Web of Science ®Google Scholar
• Bafaloukos D, Aravantinos G, Samonis G, et al. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: a Hellenic Cooperative Oncology Group study. Oncology 1999;56: 198–201
   PubMed Web of Science ®Google Scholar
• Pinelli DM, Fiorica JV, Roberts WS, et al. Chemo-therapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma. A phase II study. Gynecol Oncol 1996;60:462–7
   PubMed Web of Science ®Google Scholar
• Kung F-T, Chen W-J, Chou H-H, Ko S-F, Chang S-Y. Conservative management of early endo-metrial adenocarcinoma with repeat curettage and hormone therapy under assistance of hysteroscopy and laparoscopy. Hum Reprod 1997;12:1649–53
   Google Scholar
• Ogawa S, Koike T, Shibahara H, et al. Assisted reproductive technologies in conjunction with conservatively treated endometrial adeno-carcinoma. Gynecol Obstet Invest 2001;51:214–16
   PubMed Web of Science ®Google Scholar